Farmatsevtichnii zhurnal最新文献

{"title":"Approaches to synthesis of ([1,2,4]triazolo[1,5-c]quinazolin-2-yl)benzoic acids as potential anti-inflammators","authors":"Н. І. Красовська","doi":"10.32352/0367-3057.3.22.05","DOIUrl":"https://doi.org/10.32352/0367-3057.3.22.05","url":null,"abstract":"Despite their high efficacy NSAIDs have significant side effects due to non-selective inhibition of COX-1 and COX-2. Due to this, medical chemists still pay considerable attention to their design and synthesis, in particular the creation of hybrid molecules that combine in their structure a fragment with anti-inflammatory activity and the quinazoline heterocycle. \u0000The aim of the present study is to develop methods for the synthesis of [1,2,4]triazolo[1,5-c]quinazolin-2-yl)benzoic acids as potential anti-inflammatory agents. \u0000Quinazolin-4(3H)-ylidene)hydrazides (hydrazones) of benzenedicarboxylic acids, their esters, products of their heterocyclization and nucleophilic degradation were the subjects of the study. The structure of the synthesized compounds was confirmed by elemental analysis and NMR spectroscopy. Anti-inflammatory activity was studied in a model of acute aseptic inflammation («carrageenan test») in rats. \u0000Possibilities and limitations of synthesis of [1,2,4]triazolo[1,5-c]quinazolin-2-yl)benzoic acids and their esters via hetero­cyclization of the corresponding hydrazides and hydrazones oxidative cyclization are shown. It was found that the hydrolysis of 4-[(1,2,4]triazolo[1,5-c]quinazolin-2-yl)benzoic acid esters is not a preparative method for the synthesis of the target acids, due to the hydrolytic cleavage of the pyrimidine cycle. Compounds 3, 4 and 6 with moderate anti-inflammatory activity have been identified, which can be used for further structural modification. \u0000Conclusions. It was found that quinazolin-4(3H)-ylidene)hydrazides (hydrazones) of benzenedicarboxylic acids and their esters under the conditions of heterocyclization and oxidative cyclization form [1,2,4]triazolo[1,5-c]quinazolin-2-yl)benzoic acids and their esters. The synthesized compounds are carriers of anti-inflammatory activity and promising for further research.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42182989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of pharmaceutical factors on the dissolution profile of granules for oral suspension with nimesulide","authors":"К. В. Тарапон, О. В. Тригубчак","doi":"10.32352/0367-3057.3.22.07","DOIUrl":"https://doi.org/10.32352/0367-3057.3.22.07","url":null,"abstract":"In vitro dissolution profiles are investigated to predict the behavior of the drug in the body and to establish its effectiveness. The choice of medium and dissolution conditions depends on the class of BSC of the active substance or substances that are part of the drug. In this work, nimesulide was chosen as a model substance, which is a sparingly soluble substance of class II BSC, when bioavailability is limited only by dissolution. \u0000The aim of the work was to establish optimal conditions for determining the dissolution profiles of Nimesulide, granules for oral solution, 100 mg/2 g and to study the effect of compositional variables on the release of API. \u0000The subject of the study was granules for oral suspension, made on the basis of nimesulide. In the experiment used the substance nimesulide 3 manufacturers, corn starch and macrogol 20 (polyethylene glycol) cetostearyl ether. The particle size of the substances was investigated by laser diffraction. Determination of nimesulide release was performed by HPLC. \u0000The results of the study of the dissolution profiles of the drug Aulin, granules for oral suspension in pH 6.8, 7.5 and 7.8, where the active substance is not completely released. The addition of surfactants was used to increase the solubility of the drug. It has been experimentally confirmed that when using API nimesulide with a particle size D (90) = 64 μm, the release profiles are below the comparison drug. The similarity of the dissolution profiles of the test agent and the comparison drug provide API with a particle size D (90) < 30 μm. The dependence of the dissolution profile on the amounts of corn starch and macrogol 20 (polyethylene glycol) of cetostearyl ether is given, their optimal content in the composition of the drug is established. \u0000In the result of the work, the influence of research conditions on the dissolution profile of Aulin, granules for oral suspension, 100 mg/2 g was studied. pH 6.8 + 1% tween 80 and pH 7.4 + 0.5% tween 80 were chosen as optimal media. Experiments showed that the particle size of API nimesulide D (90) < 30 μm ensures compliance with the drug Nimesulide, granules for oral suspension, 100 mg/2 g by dissolution profiles. Increasing the amount of corn starch in the composition of the drug accelerates the dissolution of the granules and, as a consequence, raises the first points of the release profile of API. The use of 0.5% corn starch provides the dissolution profile closest to the comparison drug. To completely release API as a solubilizer, it is advisable to add 1% macrogol 20 (polyethylene glycol) cetostearyl ether.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44375470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of centralized public procurement of medicines in Ukraine with the involvement of international organizations","authors":"В. С. Злагода, Т. А. Германюк, Л. О. Бобрицька, О. С. Шпичак, В. М. Назаркіна","doi":"10.32352/0367-3057.2.22.05","DOIUrl":"https://doi.org/10.32352/0367-3057.2.22.05","url":null,"abstract":"The Ministry of Health of Ukraine carries out centralized procurement of drugs in 40 priority areas with the involvement of international organizations «UNDP», «UNICEF» and «Crown Agents» and regional procurement from local budgets and the reimbursement program «Affordable medicines».This procedure increases drugs accessibility, medical care quality and pharmaceutical provision of the population. \u0000The aim of the work is analyze the current state and effectiveness of centralized drugs procurement through the Ministry of Health in Ukraine. \u0000The object of research is the data of official statistics, regulations, scientific publications, public module of analytics programm VI ProZorro. The research was conducted using methods of content-analysis, systematization and generalization. \u0000Analysis of the dynamics of procurement of drugs involving the Ministry of Health in 2018‒2020 revealed a trend of increasing the amount of budget funds provided for the purchase of drugs in 2020 by 60% compared in 2018. In 2020, 14 procurement programs were transferred State Enterprise «Medical Procurement of Ukraine», they were performed using the electronic system «ProZorro» with the participation of a large number of international drug companies. \u0000A comparative analysis of drugs prices purchased in 2017‒2020 in the fields of «Children's Oncology» and «Adult Oncology». The decrease in drugs prices is due to competition and direct participation of drug manufacturers in tenders; entering the market of new generics, introduction of transparent mechanisms of electronic auctions, etc. Some drugs in 2020 were purchased in higher prices due to lower order volumes; quarantine restrictions, including import restrictions; rising prices for substances for the manufacture of drugs. \u0000Centralized procurement of drugs and medical commodities in Ukraine is carried out by the Ministry of Health with the involvement of international organizations «UNDP», «UNICEF» and «Crown Agents». These are temporary measures implemented in 2015 in connection with the reform of the public procurement system, aimed at reducing corruption risks and improving the pharmaceutical supply of the population. Such purchases are made in 40 fields, the total amount is about UAH 6 billion per year. \u0000Involvement of international organizations in centralized public procurement of medicines in Ukraine and implementation of a reimbursement program for medicines, including for the treatment of cardiovascular diseases reduces the price and ensures the availability of drugs for the population.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43113050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organization of pharmaceutical provision of patients with pulmonary hypertension on the example of Kyiv","authors":"І. С. Даценко, А. В. Кабачна, В. С. Гульпа","doi":"10.32352/0367-3057.2.22.01","DOIUrl":"https://doi.org/10.32352/0367-3057.2.22.01","url":null,"abstract":"In Ukraine, pharmaceutical provision of patients with pulmonary hypertension (PH) as a rare (orphan) disease is one of the important components of the State policy. Despite the permanent reform of the medical and pharmaceutical sector, a significant number of problems in the formation of a balanced system for providing the necessary medicinal products (MP) to orphan patients have not yet been resolved. \u0000The purpose of the study is to study the process of pharmaceutical provision of patients with PH, using the example of Kyiv. \u0000Information on MP purchases for patients in Kyiv, included in the Unified Clinical Protocol for Emergency, Primary, Secondary (Specialized) Medical Care Pulmonary Hypertension in Adults for the State and local budgets for 2018–2021, has been chosen as the object of the study. We have used system-review, documentary, and marketing research methods. \u0000The result of the analysis of the annual need for 2018–2021 in INN, necessary for the pharmaceutical provision of Kyiv patients with PH, has shown that the annual decrease in funding compared to 2018, namely: in 2019– by 17.54%, in 2020– by 32.52%, in 2021 – by 50.08%, due to a decrease in the cost of INN Sildenafil (Sildenafilum) by an average of 89.21% annually, compared with the cost in 2018. \u0000At the same time, the state of providing MP for patients with PH in Kyiv for the period 2018–2021 indicates that the total need for them was met at the expense of the State Budget of Ukraine and the budget of Kyiv for the implementation of the City Target Program «Health of Kievans» in 2018 – by 81.46%, and in 2019 – by 91.67% of the need. \u0000The supply of MP ordered for 2020 for the treatment of PH at the expense of the State Budget took place only at the end of 2021. Only Iloprost (Iloprostum) of the six supplies of INN ordered was completed, which accounted for 82.27% of the declared need. \u0000In 2021, only Sildenafil (Sildenafilum) was purchased at the expense of the State Budget of Ukraine, which is 8% of the need to provide treatment for patients with PH in the city of Kyiv. The City Target Program «Health of Kievans» for 2021 does not provide for expenses in the «Pulmonary Hypertension» direction. \u0000Thus, the results of a study of the organization of pharmaceutical support for Kyiv residents with PH indicate that there are no financial guarantees for the provision of free medical care to patients with rare (orphan) diseases.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46396726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of antiasthmatic drugs for inhalation in the pharmaceutical market of Ukraine and dynamics of their consumption","authors":"О. В. Ткачова, Я. О. Бутко","doi":"10.32352/0367-3057.2.22.02","DOIUrl":"https://doi.org/10.32352/0367-3057.2.22.02","url":null,"abstract":"Bronchial asthma (BA) is a common disease, as today the world suffers from about 300 million people. The number of patients with severe and complicated forms of BA is growing every year due to untimely diagnosis of the disease and late appointment of basic therapy. Complications cause disability in patients and increase mortality. \u0000The purpose of this work was to study the range and consumption in Ukraine of antiasthmatic drugs for inhalation (ADI), intended for the treatment of BA for the period 2018–2020. \u0000The analysis of the range and volumes of consumption of ADI was carried out according to the system of research of the market of medicines «Pharmstandard» of the company «Morion». Consumption estimates were made using the ATC/DDD methodology. DDDs/1 000 inhabitants/day (DID, DDDs per 1 000 inhabitants per day) was used as a unit of measurement. \u0000The results showed that in the pharmaceutical market of Ukraine during 2018–2020 used 61–64 trade names (TN) ADI, of which 11–13 TN were domestically produced and 50–51 TN – foreign manufacturers. Retail prices for ADI during 2018–2020 varied widely and increased slightly each year, due to economic instability in the pharmaceutical market of Ukraine. It was found that the consumption of ADI in the period 2018–2019 increased slightly by 1.03 times – from 7.00 DID in 2018 to 7.24 DID in 2019. In 2020, the consumption of this group of drugs decreased 1.1 times – to 6.60 DID. The undisputed leader in consumption in Ukraine was salbutamol (3.53–3.56 DID), which is probably due to the clinical efficacy and sufficient safety of the drug, greater availability of salbutamol for the population due to the wide range of generic drugs in Ukraine. market and the state program «Affordable Medicines». The second place was taken by the combination of fenoterol + ipratropium bromide (0.81–0.85 DID), which is used in adults and children for the immediate treatment of sudden attacks of bronchospasm in BA. The third place in terms of consumption in Ukraine was occupied by the combination of salmeterol + fluticasone (0.52–0.54 DID), which is mainly prescribed to patients with moderate and severe asthma.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47026380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy decametoxin in vitro for quick inactivation of respiratory coronavirus","authors":"І. В. Дзюблик, О. П. Трохименко, С. О. Соловйов, В. В. Трохимчук, О. Л. Боророва, О. К. Яковенко","doi":"10.32352/0367-3057.2.22.09","DOIUrl":"https://doi.org/10.32352/0367-3057.2.22.09","url":null,"abstract":"Despite the fact that specific prophylaxis agents have already been widely introduced into medical practice in all countries of the world, and antiviral drugs are being developed and are undergoing the first stages of clinical trials, SARS-CoV-2 continues to spread in the human population. In this regard, an urgent medical problem today is the expansion of the arsenal of effective disinfectants and antiseptics, the action of which would be aimed at the rapid and complete inactivation of extracellular coronavirus, which is a very important element in controlling the spread of COVID-19. \u0000The aim of the study was to evaluate the ability of decamethoxin to have a virucidal effect against SARS-COV-2 and other human coronaviruses on the model of respiratory coronavirus IBV (infectious bronchitis virus) with an exposure time of 30, 60 and 120 seconds. \u0000Classical and modern virological research methods were used in the work: determination of the cytotoxic effect of decamethoxin in cell culture by the effect on their viability, cultivation, accumulation and determination of the infectious titer of IBV by cytopathic action in cell culture; assessment of the virucidal effect of decamethoxin by the suspension method to determine the residual infectious titer of the virus in cell culture by the method of limiting dilutions. \u0000The effectiveness of the antiseptic decamethoxin from the group of quaternary ammonium compounds was studied in relation to the prototype strain of the IBV (infection bronchitis virus) coronavirus family in vitro. It has been established that an isotonic solution of decamethoxin at a concentration of 100 μg/ml completely inactivates 3.0 lg(TCD50/0.1 ml) of the prototype respiratory coronavirus strain with a clinically significant contact time of 30–120 seconds at room temperature(18–24 оС). Decamethoxine has been shown to be an effective, fast-acting antiseptic capable of completely inactivating a prototype coronavirus strain. The revealed virucidal properties of decamethoxine in pharmacopoeially significant concentrations in relation to coronavirus allow to recommend it as an antiseptic in the development of methods for non-specific prevention of coronavirus infection in humans.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41965289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tools for assessing the quality of life of patients with dry eye syndrome","authors":"Ю. О. Томашевська","doi":"10.32352/0367-3057.2.22.04","DOIUrl":"https://doi.org/10.32352/0367-3057.2.22.04","url":null,"abstract":"The negative influence of the dry eye syndrome on the quality of patients’ life is primarily determined by a decrease in visual performance. Quality of life in dry eye syndrome is a complex, multicomponent phenomenon that is influenced by a number of factors. The timely prescription of properly selected substitution therapy medications will help to improve the patients’ quality of life, which is one of the criteria of human health. \u0000Purpose – development of a questionnaire to analyze the quality of life of patients with dry eye syndrome. \u0000Methods of generalization, system-review and comparative analysis were used. \u0000While analyzing the existing questionnaires, whose main purpose is to assess the condition of patients with dry eye syndrome, we evaluated the advantages and disadvantages of certain questionnaires when it comes to determining the effectiveness of the prescribed therapy using the «quality of life» integrated indicator as well as instrumental research methods. A questionnaire was developed, which allows to identify the relationship between objective instrumental data, the influence of environmental factors, the severity of the dry eye syndrome symptoms, impact on daily activities and social life of the patients. \u0000The existing questionnaires that aim to determine the severity of symptoms of the dry eye syndrome are an indirect tool for assessing the quality of life, but do not allow to take into account the impact of dry eye syndrome on various areas of a patient's life. The created questionnaire makes it possible to take into account and conduct the dynamic analysis of not only the subjective feelings of the patient, but also to compare them with indicators describing the condition of tear film layers, which had been obtained as a result of an instrumental method of diagnostics using Lacrygiag. In addition, this weekly diary allows to determine the benefits of individualized pathogenically substantiated choice of substitution therapy medications for the treatment of patients with dry eye syndrome. Significant attention is paid to the presence of concomitant pathologies, as well as selected pharmacotherapy methods, as they significantly affect the course and outcome of substitution therapy for dry eye syndrome.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46253568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of stability of anti-scarring ointment with water-soluble proteinpolysaccharidic complex of the fungus Pleurotus ostreatus during the storage","authors":"О. А. Колпакова, Н. В. Кучеренко","doi":"10.32352/0367-3057.2.22.07","DOIUrl":"https://doi.org/10.32352/0367-3057.2.22.07","url":null,"abstract":"The problem of the treatment of scar tissue of the skin is quite relevant.The most affordable, convenient and comfortable way to treat scar formation is the use of soft dosage forms.So developing an effective ointment with anti-scarred activity is an urgent task of pharmaceutical technology. One of the important tasks in the process of creating original medicines is obtaining stable storing and using pharmaceutical products. For establish the shelf life it was necessary to determine the time during which the created medicine will be able to maintain stability and meet all the requirements stated in the regulatory documentation. \u0000The aimisthe study of stability of experimental samples of ointment composition with anti-scarred activity with water-soluble protein-polysaccharide complex of Pleurotus ostreatus mushroom and determination of the optimal shelf life of the created ointment. \u0000The object of the study was an original ointment composition based on an emulsion, the active component of which was a water-soluble protein-polysaccharide complex of Pleurotus ostreatus mushroom. Ointment samples were placed in polymer containers, which were hermetically sealed and stored in a dark place at room temperature (+15–25 °C) and in a refrigerator (+2–8 °C). Studies of the stability of the soft dosage form were performed on organoleptic and physicochemical parameters (description, homogeneity, pH, identification, colloidal and thermal stability, quantification and signs of microbial contamination). Measurements were performed on five lots of ointment samples after preparation and every 6 months for 3 years. \u0000The results of the study of the quality of anti-scarring ointment with water-soluble protein-polysaccharide complex of Pleurotus ostreatus mushroom indicate a rational choice of auxiliary substances and their concentration, the choice of the optimal technological process and the lack of interaction between the components of the medicine. \u0000On the basis of the conducted researches it is proved that anti-scarring ointment with water-soluble protein-polysaccharide complex of Pleurotus ostreatus mushroom remains stable for 2 years at the temperature from +2 to + 25 °С.Thus, it was found that the study samples of ointments during this period have satisfactory technological parameters.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44870161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the list and availability of medicines used for the treatment of atopic dermatitis in Ukraine","authors":"О. М. Заліська, Н. М. Максимович, З. О. Заболотня, Б. М. Заліський","doi":"10.32352/0367-3057.2.22.03","DOIUrl":"https://doi.org/10.32352/0367-3057.2.22.03","url":null,"abstract":"The prevalence of atopic dermatitis (AD) is growing rapidly among the population, treatment protocols need to be reviewed, taking into account evidence-based medicine data and the introduction of new drugs and new forms in the country's market. \u0000The aim of this study was to analyse the pharmaceutical component of treatment protocols in Ukraine, to conduct a comparative analysis of the list of medicines registered on the pharmaceutical market on 2022 (also in comparison with 2016). To determine the socio-economic affordability of TCGS for the treatment of AD at the regional level based on the availability ratio. \u0000The objects of the study were topical glucocorticosteroids (TGCS) preparations according to the State Register of Medicines of Ukraine and the online resource «Apteka online». Analysis methods: information analysis, content analysis, marketing analysis, systematization and generalization. \u0000The study of domestic protocols and the British recommendations for the treatment of AD showed that TGCS with evidence-based effectiveness are prescribed as first-line drugs, but domestic documents for the treatment of AD from 2016 need to be revised, taking into account actual evidence-based data. The results of this study of the TGCS assortment showed that as of February 1, 2022, there were 13 INN TGCS for the treatment of AD, corresponding to 104 trade names (TN) on the Ukrainian market. In 2016–2022, the assortment of TGKS increased in terms of TN by 10.6%, while imports grew by 16.1%, which indicates a positive trend in the segment. It was revealed that, compared with 2016, there is a negative trend of reducing the number of domestic producers of TCGS by 18.1%. Consequently, the share of imported TGCS preparations is 62.5%, which contributes to the growth of treatment costs. \u0000An analysis of the assortment of TKGS according to the dosage form of the release shows that the main share among domestic drugs is ointments for, and for imported drugs – cream, but very small amounts in the form of lotions, emulsions. It was found that two medicines are low available: methylprednisolone aceponate, bemethasone, medicines have an average availability: mometasone furoate, bemethasone (lotion). It was revealed that the majority of domestically produced drugs are available to patients. It has been established that the range of TGCS in the treatment of AD is import-dependent, 5 INNs are not available in domestic production. \u0000It has been substantiated that pharmacist should be aware of new TGCS, the features and duration of their administration in order to ensure good pharmaceutical care for the effective treatment of AD.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43286711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research the influence of excipients on the technological properties of captopril fast dissolving films","authors":"М. Б. Демчук, Ю. Я. Мельник, Н. В. Маланчук, Т. А. Грошовий, В. Й. Скорохода","doi":"10.32352/0367-3057.2.22.06","DOIUrl":"https://doi.org/10.32352/0367-3057.2.22.06","url":null,"abstract":"Drug-loaded films are of great interest among fast-dissolving drug-delivery systems. The creation of fast-dissolving films for the treatment of cardiovascular diseases is important.The first inhibitor of angiotensin-converting enzyme to appear on the world market was captopril, which is used to treat hypertension, chronic heart failure and others. Captopril has an antihypertensive effect, which manifests itself within 5–15 minutes after sublingual administration. \u0000The aim of our study was to develop the technology of captopril fast dissolving films by solvent casting method and analyze the influence of groups of excipients on technological properties of the films. \u0000The influence of the character of polymers, plasticizers, disintegrants and sweeteners on the technological properties of experimental batches of captopril fast dissolving films was studied. Such technological indicators as uniformity of weight, thickness, swelling index,tensile strength, elongationand disintegration time were studied. \u0000The influence of excipients' composition on the technological indicators of captopril fast dissolving films has been researched. It was found out that the effect of the type of polymer had the decisive influence on all parameters of films.The selected plasticizer determined the elasticity (films' elongation), film thickness and weight variation. Optimal values of the average weight and thickness of captopril films are provided by the use of a polymer in the combination of HPMC with PEG 4000 or a combination of HPMC with PEG 6000, as a plasticizer – glycerin or PEG 400. The best results of films' swelling were obtained with the introduction of HPMC brands Metolose® 90 SH 100 000 or Metolose® 65 SH 50, Polyplasdone XL-10 crospovidone, propylene glycol and sorbitol. The disintegration time less than 3 min was observed in all investigated film compositions, except those containing PVA. The highest value of tensile strength for captopril films was obtained using HPMC brand Metolose® 65 SH 50 or Metolose®90 SH 100 000. \u0000Using the desirability function, the optimal excipients within the studied groups were selected.It has been established that the optimal values of the technological parameters of captopril films can be achieved using Hydroxypropyl MethylcelluloseVivapharm® E15, polyethylene glycol 400, sodium starch glycolate and sorbitol.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42308954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}